Jun 21, 2023 8:00 am EDT Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference
Jun 12, 2023 8:00 am EDT Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023
May 24, 2023 4:05 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
May 2, 2023 8:30 am EDT Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
Apr 25, 2023 8:00 am EDT Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
Mar 30, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
Mar 23, 2023 8:00 am EDT Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting